OMS, 5 de diciembre de
2014
Contenido
Regulatory Matters
Agomelatine
................................................................................................
4
Azithromycin
...............................................................................................
4
Basiliximab..................................................................................................
4
Clopidogrel
..................................................................................................
5
Colistin,
colistimethate sodium (known as polymyxins)
.............................. 5
Colobreathe®
(colistimethate sodium dry powder for inhalation) ............... 6
Denosumab
.................................................................................................
7
Immunoglobulins
.........................................................................................
7
Ponatinib
....................................................................................................
8
Rituximab
...................................................................................................
8
Sulfamethoxazole-trimethoprim
.....................................................................
9
Zopiclone
....................................................................................................
9
Safety of medicines
Amitriptyline...............................................................................................
11
Boceprevir and
telaprevir
.............................................................................
11
Interferon beta
...........................................................................................
11
Zoledronic acid
...........................................................................................
11
Signal
Agomelatine and
thrombocytopenia
............................................................... 13
Dronedarone and
ventricular arrhythmia
........................................................ 18
Dronedarone and vision
abnormal
................................................................. 28
Feature
16th International
Conference of Drug Regulatory Authorities (ICDRA)
and its recommendations
.............................................................................
36
Número completo
disponible en http://bit.ly/1yUGlUj
No hay comentarios:
Publicar un comentario